RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Tocilizumab may improve survival in sickest COVID-19 patients, scientists say
Among other treatments, they said tocilizumab was considered for off-label usage for the patients whose respiratory symptoms were declining -- many of whom were requiring mechanical ventilator support. In the observational study, the researchers noted that 210 patients received tocilizumab, and the other 420 did not. (Source: The Economic Times)
Source: The Economic Times - August 20, 2020 Category: Consumer Health News Source Type: news

Observational study identifies drug that improves survival in sickest COVID-19 patients
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). (Source: World Pharma News)
Source: World Pharma News - August 19, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Observational study identifies drug that improves survival in sickest COVID-19 patients
(Hackensack Meridian Health) A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). The findings were published in The Lancet Rheumatology on Aug. 14, and Hackensack Meridian Health researchers have updated the U.S. Food and Drug Administration and other national leaders of the findings to potentially accelerate improved outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 19, 2020 Category: Cancer & Oncology Source Type: news

Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), version 1: 30 July 2020, NHS England and NHS Improvement
In response to the public health emergency posed by coronavirus disease 2019 (COVID-19), NHS England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with or at risk of COVID-19. This document sets out the recommendations for the use of tocilizumab in giant cell arteritis (GCA) in the context of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2020 Category: Consumer Health News Source Type: news

Drug vignettes: Tocilizumab, CEBM
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 5, 2020 Category: Consumer Health News Source Type: news

Coronavirus: Tocilizumab doesn't work on infection, say studies
Doctors in New Jersey have said there is no evidence to support the use of tocilizumab, marketed as Actemra, to manage the often fatal cytokine storm seen in Covid-19 patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2020 Category: Consumer Health News Source Type: news

Better outcomes in severe COVID-19 patients administered interleukin-6 inhibitors early
(Boston Medical Center) New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses. The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 4, 2020 Category: Biology Source Type: news

Tocilizumab ± methotrexate not a cost-effective option in early RA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news

Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), NHS England (published 29th July 2020)
This interim policy proposition provides an option for some patients on tocilizumab for GCA nearing the end of their prescription to continue past 12 months up to April 2021. The basis for this is reducing the risk of a flare up of the disease in a vulnerable group of patients in the context of COVID-19. A flare up would lead to hospital interactions and high dose steroid medication, both of which may increase the risk and severity of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 30, 2020 Category: Consumer Health News Source Type: news

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
Basel, 29 July - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III COVACTA study of Actemra ®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra. The COVACTA study did not identify any new safety signals for Actemra/RoActemra. Further analysis of the trial results is ...
Source: Roche Media News - July 29, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
Basel, 29 July - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III COVACTA study of Actemra ®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra. The COVACTA study did not identify any new safety signals for Actemra/RoActemra. Further analysis of the trial results is ...
Source: Roche Investor Update - July 29, 2020 Category: Pharmaceuticals Source Type: news

Health ministry asks DGCI to ensure equitable distribution of Remdesivir, Tocilizumab drugs
The ministry has shot off a letter to the Drugs Controller General of India (DCGI), asking it to ascertain how many states and Union territories (UTs) have been covered and which of them are left, as far as the availability and distribution of these drugs by the respective companies is concerned. (Source: The Economic Times)
Source: The Economic Times - July 28, 2020 Category: Consumer Health News Source Type: news

Arthritis anti-inflammatory treatment could halt immune system 'storm' to coronavirus
Doctors say anti-inflammatory treatment tocilizumab could save lives by halting the immune system 'storm' that has killed thousands of virus patients. (Source: the Mail online | Health)
Source: the Mail online | Health - July 28, 2020 Category: Consumer Health News Source Type: news

Kenya: Kenyan Patients Enrolled On Clinical Trial for Coronavirus-Related Pneumonia Treatment
[Capital FM] Nairobi -- Pharmaceutical firm Roche on Tuesday announced the enrollment of Kenyan patients on a clinical trial to evaluate the efficacy of tocilizumab drug for coronavirus-related pneumonia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 21, 2020 Category: African Health Source Type: news